The trend shows that monospecific antibodies against LAG-3 continue to be the main antagonists, followed by multispecific t, treatment methods using known LAG-3 antagonists, LAG-3 binding peptides, and LAG-3 binding small molecules. The monospecific antibodies encelimab, miptenalimab, and the bispecific antibodies tobemstomig, IBI323, ABL501, fanastomig, and FS118 are added, during this period, to the potential drugs targeting LAG-3.

12 days ago

Review • Journal

CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • CD4 (CD4 Molecule)

FS118 • ABL501 • IBI-323 • encelimab (TSR-033) • miptenalimab (BI 754111) • tobemstomig (RG6139)

2years

Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC (clinicaltrials.gov)

P2, N=70, Recruiting, Hunan Province Tumor Hospital | Not yet recruiting --> Recruiting | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Dec 2024 --> Dec 2025

2 years ago

Enrollment open • Trial completion date • Trial primary completion date

ALK (Anaplastic lymphoma kinase)

ALK rearrangement

Avastin (bevacizumab) • Alecensa (alectinib) • IBI-323

over2years

Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC (clinicaltrials.gov)

P2, N=80, Not yet recruiting, Hunan Province Tumor Hospital | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Dec 2023 --> Dec 2024

over 2 years ago

Trial completion date • Trial primary completion date

ALK (Anaplastic lymphoma kinase)

ALK rearrangement

Avastin (bevacizumab) • Alecensa (alectinib) • IBI-323